Acetyl-CoA carboxylase inhibitors in non-alcoholic steatohepatitis: Is there a benefit?

Table 1 Major findings of preclinical and clinical studies that evaluated the effects of acetyl-CoA carboxylase inhibitors in non-alcoholic steatohepatitis

Population	ACC inhibitor	Major findings	Ref.
Mice with NASH	Firsocostat (GS-0976)	↓ Hepatic steatosis, inflammation and fibrosis	[13,14]
High-fructose-fed rats	A structural analog of firsocostat	↓ Hepatic steatosis; ↓ hepatic insulin resistance	[15]
Zucker diabetic fatty rats	ND-630	↓ Hepatic steatosis	[16]
Rat model of NASH	PF-05221304	↓ Hepatic steatosis, inflammation and fibrosis	[17]
Rat model of NASH	MK-4074	No effect on hepatic fibrosis	[21]
Rat model of NASH	ND-654	↓ Hepatic steatosis; Delayed progression of hepatocellular cancer	[22]
10 patients with NASH	Firsocostat	↓ Hepatic steatosis and fibrosis	[23]
126 patients with NASH	Firsocostat	↓ Hepatic steatosis and tissue inhibitor of metalloproteinase-1 levels	[24]
392 patients with NASH and bridging fibrosis or compensated cirrhosis (F3-F4)	Firsocostat	↓ Hepatic steatosis and stiffness	[25]
Healthy subjects	PF-05221304	Dose-dependent suppression of de novo lipogenesis	[26]
Overweight and/or obese adult males	ND-630	Suppression of de novo lipogenesis	[27]
30 patients with non-alcoholic fatty liver	MK-4074	↓ Hepatic steatosis	[28]